ABSTRACT
In recent years, in addition to the use of antipsychotics, case reports of extra-pyramidal symptoms (EPS) associated with the use of selective serotonin reuptake inhibitors have been reported with increasing frequency. Tardive dyskinesia, one of the EPS, is a serious movement disorder that is difficult to treat and can lead to impaired social functioning. Occurrence during the stable course of the treatment may increase the risk of being undiagnosed in the clinic. In this study, tardive dyskinesia symptoms, differential diagnosis and treatment process developed after fluoxetine dose increase in an adolescent patient with autism who has been using fluoxetine treatment for the last 6 years in addition to dual atypical antipsychotic (risperidone and aripiprazole) treatment, which she has been using for 11 years, are shared.
Keywords: Fluoxetine, tardive dyskinesia, antipsychotic, child, autism